Abstract
Treatment of secondary haemosiderosis with desferrioxamine (DFO) was evaluated in children and adolescents treated by chronic haemodialysis. Ten patients were treated with intravenous DFO (25 mg/kg body weight). Three patients received DFO throughout dialysis, four were treated only during the last hour of each dialysis session, and three other patients were successively treated with DFO according to both regimens. A significant decrease and normalisation of serum ferritin was achieved only with DFO administered during the last hour of dialysis. In some patients blood haemoglobin (Hb) increased during treatment. Although serum ferritin levels remained normal, Hb levels returned to pretreatment values following discontinuation of DFO treatment. Visual and auditory neurotoxicity was not noticed but increased systemic infections were observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- DFO:
-
desferrioxamine
References
Baker LRI, Barnett MD, Brozovic B, Cattell WR, Ackrill P, Mc Alister J, Nimmon C (1976) Haemosiderosis in a patient on regular haemodialysis: treatment by Desferrioxamine. Clin Nephrol 6:326–328
Cases A, Kelly J, Sabater J, Campistol JM, Torras A, Montolium J, Lopez, I, Revert L (1988) Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving deferrioxamine. Clin Nephrol 29:176–178
Chiu HY, Flynn DM, Hoffbrand AV (1986) Infection with yersinia enterocolitica in patients with iron overload. Br Med J 292:97
De La Serna FJ, Gilsanz F, Railope LM, Prager M, Rodicio JL, Alcazar JM (1988) Improvement in the erythropoiesis of chronic haemodialysis patients with desferrioxamine. Lancet 1:1009–1011
Eijgenraam FJ, Donckerwolcke RA, Dijken PJ van (1988) Diagnosis and treatment, of iron overload in pediatric patients on chronic haemodialysis. Pediatr Nephrol 2:303–308
Ellis D (1979) Serum ferritin compared with other indices of iron status in children and teenagers undergoing maintenance haemodialysis. Clin Chem 25:741–744
Goodill JJ, Abuelo JG (1987) Mucormycosis: a new risk of desferrioxamine therapy in dialysis patients with aluminium or iron overload. N Engl J Med 317:54
Marco-Franco JE, Alarcon A, Morey A, Piza C, Bestard J, Mairata S, Galmes A, Dolmau M (1982) Serum ferritin in haemodialysis. Nephron 32:57–59
Mc Gonigle RJS, Keogh AM, Weston MJ, Parsons V (1984) Iron status in chronic haemodialysis patients — treatment of transfusional iron overload with desferrioxamine. Dial Transplant 13:214–219
Miles LFM, Lipschitz DA, Bieber LP, Cook JD (1978) Measurement of serum ferritin by a 2-site immunoradiometric assay. Anal Biochem 61:209–224
Müller-Wiefel De, Wolf E, Schönberg D, Schärer K (1978) Serum ferritin concentrations in children with chronic renal failure. Proc Eur Dial Transplant Assoc 15:625–627
Müller-Wiefel De, Waldherr, R, Feist D Kaick G van (1984) The assessment of iron stores in children on regular dialysis treatment. Contrib Nephrol 38:141–152
Olivieri NF, Buncic JR, Chewv E, Gallant T, Harrison RV, Keenan N, LOgan W, Mitchell D, Ricci G, Skarf B, Taylor M, Freedman MH (1986) Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxamine infusions. N Engl J Med 314:869–873
Praga M, Andres A, La Serna J de, Ruilope LM, Nieto J, Estenoz J, Millet VG, Arnaiz F, Rodico JL (1987) Improvement of anemia with desferrioxamine in haemodialysis patients. Nephrol Dial Transplant 2:243–247
Robins-Browne RM, Pepic JK (1983) Desferrioxamine and systemic yersinosis. Lancet II:1973
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eijgenraam, F.J., Donckerwolcke, R.A. Treatment of iron overload in children and adolescents on chronic haemodialysis. Eur J Pediatr 149, 359–362 (1990). https://doi.org/10.1007/BF02171568
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02171568